Today marks a new chapter for WellTheory — and for the millions of Americans living with autoimmune disease.
We’re proud to announce our $14M Series A funding led by General Catalyst, with participation from 7wire Ventures, Ingeborg Investments, Accel, Box Group, and Up2 Opportunity Fund.
This milestone means so much more than funding. It’s proof that the world is starting to pay attention to an epidemic that’s been ignored for far too long.
Read More – Class 3 Technologies Raises $3.5M in Seed Funding
The Growing Autoimmune Crisis
Autoimmune disease affects over 50 million Americans, 80% of whom are women. Yet for decades, it’s been misunderstood, underdiagnosed, and overlooked.
These conditions are rising faster than any other disease category, doubling in prevalence in just 30 years.
The costs are staggering. Autoimmune disease now represents a $150B+ annual market, a figure that continues to climb as new immunology drugs come to market. These conditions account for 50% of all specialty drug spend, which has risen 459% over the past decade.
Employers and health plans feel this burden acutely, but autoimmune diseases are often invisible in claims data — scattered across specialties, never tied back to the same root cause.
Behind those numbers are real people. People who have spent years searching for answers, only to be told their labs look “normal” or that their symptoms are “all in their head.”
From Personal Stories to a Shared Mission
I know that story because I lived it.
At 25, I was bedridden and desperate for answers. I spent months cycling through specialists and tests, hoping someone would finally connect the dots.
When I was eventually diagnosed with an autoimmune condition, I realized just how broken the system was and how many others were being left behind. Along the way, I connected with my co-founders, Claire and Wallace, whose lives had also been touched by autoimmune disease.
Together, we decided to build the solution we all wished had existed at the start of our journeys — care that’s personalized, proactive, and rooted in compassion.
When we launched WellTheory, our goal was simple but ambitious: to reimagine autoimmune care from the ground up with a model that looks at the whole person, not just the diagnosis.
What started as a small, passionate community has grown into something much larger. Today, we’re seeing thousands of members reduce symptoms, regain energy, and rebuild their lives after years of being dismissed.
Employers and health plans are also recognizing what patients have known all along: autoimmune conditions can’t be treated in silos. They’re now turning to WellTheory to address autoimmune conditions at scale — not as isolated diseases, but as systemic issues affecting every aspect of well-being and productivity.
Read More – Reducto Raises $75M in Series B Funding
